Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × polatuzumab vedotin × Clear all

Phase

Phase 1/2 7 Phase 1 2 Phase 3 1 Phase 2 1

Status

Active not recruiting 2 Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Cyclophosphamide 267 Cisplatin 254 Radiotherapy 230 Paclitaxel 222 Fluorouracil 204 Docetaxel 203 Carboplatin 199 Doxorubicin 198 Dexamethasone 151 Gemcitabine 138 Vincristine 131 Etoposide 119 Prednisone 116 Leucovorin 116 Capecitabine 116 Bevacizumab 109 Methotrexate 106 Rituximab 105 Cytarabine 99 Trastuzumab 86 Filgrastim 86 Oxaliplatin 82 pembrolizumab 68 Tamoxifen 62 Drug Therapy 62 Pemetrexed 61 Epirubicin 60 Irinotecan 57 Chemotherapy, Adjuvant 54 Granulocyte Colony-Stimulating Factor 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04182204 2025-12-22

POLARGO

Hoffmann-La Roche

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡